EMA Recommends Moderna's Updated COVID-19 Vaccine for EU Authorization

Moderna, Inc. has announced a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding their updated COVID-19 vaccine. This formulation targets the SARS-CoV-2 variant LP.8.1 and is intended for individuals aged six months and older. Pending authorization from the European Commission, the vaccine could be available for the 2025-2026 vaccination season.

CEO Stéphane Bancel highlighted this development as a significant step in addressing the ongoing threat of COVID-19, particularly among vulnerable populations. The decision by the CHMP is based on various data and aligns with global health guidelines identifying LP.8.1 as a pertinent vaccine update.

Moderna is also pursuing regulatory approvals for this vaccine variant worldwide.